Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous28-Jun-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA 27.05.2022 / 15:15 Press Release (PDF)Dublin, Ireland – 27 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.8,315,019 ordinary shares in the share capital of Cosmo were represented at thi
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousCOSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA 03.05.2022 / 06:00 Press Release (PDF)Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.Eleview(R) is a sub